Two oral GLP-1 medications for weight management have now been approved in the United States, removing the injection from the decision for the first time. That lowers one barrier to starting treatment without changing anything about what a safe prescribing evaluation requires.
The FDA approved a once-daily oral semaglutide tablet for chronic weight management in December 2025, the first oral GLP-1 cleared for that use, with a launch in early January. On April 1 of this year, it approved orforglipron, a nonpeptide oral GLP-1 receptor agonist marketed as Foundayo, for adults with obesity or overweight with at least one weight-related condition. Orforglipron is notable because it can be taken at any time of day without the fasting and water restrictions the earlier oral formulation requires.
